Urothelial Carcinoma in Transplanted, Pelvic, and End Stage Kidneys

  • Roger Yau
  • Majid EshghiEmail author


The incidence of UTUC in congenital pelvic kidneys is not statistically different from the kidneys located in the true retroperitoneum with very few reported cases. The incidence of UTUC in transplanted kidneys depends on the pre-existing risks of the donor and those acquired by the recipient. The majority of these cases are reported from the Balkan region and Southeast Asia due to consumption of aristolochic acid. We will review the current available literature data in this chapter.


Upper tract urothelial cell carcinoma (UTUC) Urothelial cell carcinoma (UC) Renal transplant Pelvic kidney Autotransplant kidney De novo malignancies in end stage renal disease (ESRD) De novo malignancies in renal transplant recipients Aristolochic acid 


  1. 1.
    Abeshouse BS, Bhisitkul I. Crossed renal ectopia with and without fusion. Urol Int. 1959;9:63–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Cowan NG, et al. Renal autotransplantation: 27-year experience at 2 institutions. J Urol. 2015;194(5):1357–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades (0022–5347 (Print)).Google Scholar
  4. 4.
    Wein AJ, et al. Campbell-Walsh urology. Elsevier Health Sciences; 2015.CrossRefGoogle Scholar
  5. 5.
    Kauffman HM, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int. 2006;19(8):607–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Chuang FR, et al. Increasing transplant cancer patient survival by conversion of immunosuppressive agents (0041–1345 (Print)).Google Scholar
  7. 7.
    Zhang A, et al. A retrospective review of patients with urothelial cancer in 3370 recipients after renal transplantation: a single-center experience. World J Urol. 2015;33(5):713–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Lai MK, Tai HC, Wang SM. Urothelial carcinoma in renal transplant recipients. In: Trzcinska M, editor. Kidney transplantation—new perspectives. InTech; 2011.Google Scholar
  9. 9.
    Kao Y-L, et al. Transitional cell carcinoma in renal transplant recipients. World J Surg. 2003;27(8):912–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Li XB, et al. Transitional cell carcinoma in renal transplant recipients: a single center experience. Int J Urol. 2008;15(1):53–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Engels EA, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hevia V, et al. Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients. Case Rep Transplant. 2013;2013:196528.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet. 2000;355(9218):1886–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Stewart JH, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol. 2003;14(1):197–207.CrossRefPubMedGoogle Scholar
  15. 15.
    Prabharasuth D, et al. Management of bladder cancer after renal transplantation. Urology. 2013;81(4):813–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Master VA, et al. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol. 2004;171(3):1085–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of UrologyWestchester Medical Health Network/New York Medical CollegeValhallaUSA

Personalised recommendations